13314-96-0

Usage

Uses

Used in Pharmaceutical Industry:
2-[(phenylamino)methyl]-1H-isoindole-1,3(2H)-dione is used as a potential anti-inflammatory agent for its ability to reduce inflammation and alleviate symptoms associated with inflammatory conditions.
Used in Enzyme Inhibition:
2-[(phenylamino)methyl]-1H-isoindole-1,3(2H)-dione is used as an enzyme inhibitor to target and suppress the activity of specific enzymes involved in various biological processes, potentially leading to therapeutic benefits.
Used in Disease Treatment:
2-[(phenylamino)methyl]-1H-isoindole-1,3(2H)-dione is used as a potential treatment for various diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions, due to its ability to regulate cell signaling pathways and influence disease progression.
Used in Medicinal Chemistry Research:
2-[(phenylamino)methyl]-1H-isoindole-1,3(2H)-dione is used as a subject of ongoing research in the field of medicinal chemistry to explore its potential applications, optimize its properties, and develop new therapeutic agents based on its unique molecular structure.

Upstream product

• 136918-14-4 phthalimide 
• 50-00-0 formaldehyd 
• 62-53-3 aniline 
• 5332-26-3 N-(bromomethyl)phtalimide 
• 71-43-2 benzene 
• 118-29-6 2-(hydroxymethyl)-1H-isoindole-1,3(2H)-dione 
• 85-44-9 phthalic anhydride 

Relevant academic research and scientific papers

Crystal structure, conformation and vibrational analysis of a mannich base: 2-[(phenylamino) methyl]-isoindole-1,3-dione

The crystal structure of 2-[(phenylamino) methyl]-isoindole-1,3-dione, C15H12N2O2, crystallizes in the triclinic space group Pi with cell parameters of a = 7.1176 (2) A, b = 8.5533 (3) A, c = 10.9163 (4) A, α =

Isoindole-1,3-dione derivatives as RSK2 inhibitors: Synthesis, molecular docking simulation and SAR analysis

RSK2 (p90 ribosomal S6 kinase 2) is a serine/threonine kinase expressed in a variety of cancers. Molecular-targeted inhibition of RSK2 as a potential therapeutic strategy for human cancers has been documented. In this work, a series of isoindole-1,3-dione derivatives as novel RSK2 inhibitors were designed and synthesized from a hit discovered in our previous study. Some compounds were confirmed to be moderately potent RSK2 inhibitors with IC50 values of about 0.5 μM. Structure-activity relationship analysis and binding mode studies by molecular docking were performed.

Potent novel nonsteroidal androgen antagonists with a phthalimide skeleton

Anti-androgenic activity of various phthalimide analogs was evaluated based on inhibition of androgen-induced activation of nuclear androgen receptor (CAT assay) and on growth inhibition of the androgen-dependent clonal cell line SC-3. Some compounds showed very potent androgen-antagonistic activity.